Tybourne Capital Management HK Ltd. Has $1.72 Million Position in Zentalis Pharmaceuticals, Inc. $ZNTL

Tybourne Capital Management HK Ltd. increased its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 53.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 1,478,152 shares of the company’s stock after acquiring an additional 516,666 shares during the quarter. Zentalis Pharmaceuticals accounts for 5.0% of Tybourne Capital Management HK Ltd.’s portfolio, making the stock its 6th largest holding. Tybourne Capital Management HK Ltd.’s holdings in Zentalis Pharmaceuticals were worth $1,715,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of ZNTL. Millennium Management LLC lifted its position in Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after purchasing an additional 2,111,951 shares during the period. Acadian Asset Management LLC lifted its position in Zentalis Pharmaceuticals by 150.6% during the first quarter. Acadian Asset Management LLC now owns 2,674,035 shares of the company’s stock worth $4,244,000 after purchasing an additional 1,606,802 shares during the period. Peapod Lane Capital LLC bought a new position in shares of Zentalis Pharmaceuticals in the first quarter worth about $888,000. Nuveen LLC bought a new position in shares of Zentalis Pharmaceuticals in the first quarter worth about $807,000. Finally, GSA Capital Partners LLP lifted its holdings in shares of Zentalis Pharmaceuticals by 275.9% in the first quarter. GSA Capital Partners LLP now owns 541,975 shares of the company’s stock worth $862,000 after acquiring an additional 397,805 shares during the last quarter.

Analysts Set New Price Targets

ZNTL has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a report on Thursday, August 7th. HC Wainwright raised shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a report on Friday. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $5.84.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock opened at $1.71 on Monday. The business has a 50 day moving average of $1.62 and a 200-day moving average of $1.44. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $4.44. The company has a market capitalization of $123.36 million, a P/E ratio of -0.76 and a beta of 1.77.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.19. Equities analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.